ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga’s Virtual Healthcare Summit 2024 on March 20, 2024
14 mars 2024 07h57 HE
|
ZyVersa Therapeutics
Mr. Glover will talk about inflammasomes, and how they trigger development and spread of damaging inflammation, the culprit behind many deadly diseases.
ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100’s Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications
28 févr. 2024 07h57 HE
|
ZyVersa Therapeutics
In obesity, inflammasome activation in fat tissue triggers cell death and release of inflammatory cytokines & ASC Specks, spreading damaging inflammation.
ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option
22 févr. 2024 07h47 HE
|
ZyVersa Therapeutics
Activation of multiple inflammasome pathways and extracellular ASC specks contribute to development and progression of common neurological diseases.
ZyVersa Therapeutics Highlights Publication Indicating That Inflammasome NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications Such as Type 2 Diabetes
31 janv. 2024 07h57 HE
|
ZyVersa Therapeutics
NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications (e.g., Type 2 Diabetes, Hypertension, Heart Disease).
ZyVersa Therapeutics Announces Publication Showing AIM2 and NLRP3 Inflammasomes Promote Atherosclerosis in Diabetes, Supporting IC 100’s Rationale for Targeting ASC to Inhibit Multiple Inflammasome Pathways
06 déc. 2023 07h20 HE
|
ZyVersa Therapeutics
AIM2 and NLRP3 inflammasome activation leads to development of atherosclerotic lesions in diabetic mice.
ZyVersa Therapeutics Announces Article Published in Peer-Reviewed Biomedical Journal Demonstrating That NLRP3 Inflammasome Inhibition Attenuates Inflammatory Bowel Disease Symptoms in Animal Model
09 nov. 2023 07h35 HE
|
ZyVersa Therapeutics
NLRP3 inflammasome inhibition attenuates intestinal inflammation and tissue damage, and significantly improves symptoms in IBD animal model.
ZyVersa Therapeutics Announces Article in Peer-Reviewed Journal, Ecotoxicology and Environmental Safety, Linking Air Pollution with Development and Progression of Chronic Kidney Disease That Can Be Attenuated by Inhibiting Inflammasome NLRP3 Activation
06 nov. 2023 07h05 HE
|
ZyVersa Therapeutics
Air pollution linked with development and progression of chronic kidney disease that can be attenuated by inhibiting inflammasome NLRP3 activation.
ZyVersa Therapeutics Announces Publication in Molecular Neurobiology Reinforcing Data Demonstrating That Inflammasome ASC Inhibitor IC 100 Attenuates the Inflammatory Response Causing Neuronal Damage in Multiple Sclerosis Model, Potentially Providing Neuroprotection
01 nov. 2023 08h07 HE
|
ZyVersa Therapeutics
NLRP3 Inflammasome Inhibition Alleviates Neurological Impairment in the Brain of MS Mouse Model, Reinforcing Published Data for IC 100 in MS Mouse Model.
ZyVersa Therapeutics Announces Research Published in the Peer-Reviewed Journal Diabetes Reinforcing IC 100’s Rationale for Inhibiting ASC to Attenuate Damaging Inflammation Associated with Serious Conditions Such as Obesity-related Heart Disease
25 oct. 2023 06h50 HE
|
ZyVersa Therapeutics
Obesity exacerbates scarring of the heart through ASC-driven inflammasome activation in the heart leading to damaging inflammation.
ZyVersa Therapeutics Announces Research Published in The Journal of Clinical Investigation Reinforcing IC 100’s Rationale for Inhibiting ASC Specks to Attenuate Spread of Inflammation into Surrounding Tissues
22 sept. 2023 06h35 HE
|
ZyVersa Therapeutics
Patients with chronic kidney disease (“CKD”) exhibit chronic systemic inflammation characterized by increased circulating levels of IL-1β, IL-6, and CRP.This study demonstrated that CKD-induced IL-1β...